US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pacer WealthShield ETF

32.06

0.0000

Volume:9

Turnover:290.30

Market Cap:14.43M

PE:- -

High:32.06

Open:32.06

Low:32.06

Close:32.06

52wk High:33.83

52wk Low:31.18

Shares:450.00K

Float Shares:450.00K

Volume Ratio:0.00

T/O Rate:0.00%

Dividend:0.68

Dividend Rate:2.12%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Press Release: Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to Its Board of Directors

Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference

Press Release: Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Press Release: Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Stock-bond Correlations Seen Rising

Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026

Rhythm Pharmaceuticals: Buy Rating Reiterated on Promising PWS Data and Large Market Opportunity; $105 Price Target Unchanged

Rhythm Pharmaceuticals (RYTM) Stock After Positive Phase 2 PWS Data What Does The Valuation Suggest

Simply Wall St.

Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome

Press Release: Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026

FDA Imposes Full Clinical Hold on Aardvark's PWS Drug Candidate, Triggering Sharp Stock Decline

Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold

Press Release: Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/PWS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PWS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PWS\",,,,,undefined,":{"symbol":"PWS","market":"US","secType":"STK","nameCN":"Pacer WealthShield ETF","latestPrice":32.0568,"timestamp":1791558659465,"preClose":32.0568,"halted":0,"volume":9,"delay":0,"changeRate":0,"floatShares":450000,"shares":450000,"eps":0,"marketStatus":"Trading","change":0,"latestTime":"10-09 14:30:53 EDT","open":32.0568,"high":32.0568,"low":32.0568,"amount":290.301777,"amplitude":0,"askPrice":32.54,"askSize":1300,"bidPrice":32.48,"bidSize":1500,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791576000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"CBOE","adjPreClose":32.0568,"sharesOutstanding":950000,"nav":32.27,"aum":14521500,"dividendRate":0.021228,"bidAskSpread":0.002394,"postHourTrading":{"tag":"盘后","latestPrice":32.06,"preClose":32.0568,"latestTime":"16:10 EDT","volume":6,"amount":192.3408,"timestamp":1791490204420,"change":0.0032,"changeRate":0.0001,"amplitude":0},"volumeRatio":0.000269},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PWS\",,,,,undefined,":{"symbol":"PWS","floatShares":450000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.000269,"shares":450000,"dividePrice":0.6805,"high":32.0568,"amplitude":0,"preClose":32.0568,"low":32.0568,"week52Low":31.18,"pbRate":"--","week52High":33.83,"institutionHeld":0,"latestPrice":32.0568,"committee":0.071429,"eps":0,"divideRate":0.021228,"volume":9,"delay":0,"ttmEps":0,"open":32.0568,"prevYearClose":32.3237,"prevWeekClose":32.1643,"prevMonthClose":32.2523,"prevQuarterClose":32.2523,"fiveDayClose":32.1643,"twentyDayClose":32.6888,"sixtyDayClose":32.3977},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PWS\",params:#limit:5,,,undefined,":[{"date":"2026-09-03","symbol":"PWS","amount":0.33672,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-03","defaultRemindTime":1788442200000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-08","payableDate":"2026-09-03","currency":"USD","dateTimestamp":1788408000000,"payDate":"2026-09-08"},{"date":"2026-06-04","symbol":"PWS","amount":0.0682,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-04","defaultRemindTime":1780579800000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-08","payableDate":"2026-06-04","currency":"USD","dateTimestamp":1780545600000,"payDate":"2026-06-08"},{"date":"2026-03-05","symbol":"PWS","amount":0.016362,"announcedDate":"2026-03-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-05","defaultRemindTime":1772721000000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-09","payableDate":"2026-03-05","currency":"USD","dateTimestamp":1772686800000,"payDate":"2026-03-09"},{"date":"2025-12-30","symbol":"PWS","amount":0.25921895,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-05","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-05"},{"date":"2025-09-04","symbol":"PWS","amount":0.0796608,"announcedDate":"2025-09-03","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-04","defaultRemindTime":1756992600000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-10","payableDate":"2025-09-04","currency":"USD","dateTimestamp":1756958400000,"payDate":"2025-09-10"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PWS\",market:\"US\",,,undefined,":[{"executeDate":"2018-03-27","recordDate":"2018-03-28","paymentDate":"2018-03-29","value":0.0522982,"currency":"USD"},{"executeDate":"2018-06-26","recordDate":"2018-06-27","paymentDate":"2018-06-28","value":0.0481106,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-09-27","value":0.1105742,"currency":"USD"},{"executeDate":"2018-12-24","recordDate":"2018-12-26","paymentDate":"2018-12-27","value":0.0682115,"currency":"USD"},{"executeDate":"2019-03-26","recordDate":"2019-03-27","paymentDate":"2019-03-28","value":0.1385698,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PWS\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PWS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673741710","title":"Press Release: Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2673741710","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673741710?lang=en_us&edition=fundamental","pubTime":"2026-10-08 20:00","pubTimestamp":1791460800,"startTime":"0","endTime":"0","summary":"Brings more than 25 years of experience in clinical strategy, biostatistics and regulatory submissions from Abivax, Alumis, MyoKardia and Genentech/RocheSAN DIEGO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Aa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","R","BK4007","BK4232","BK4022","PWS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672309780","title":"Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2672309780","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672309780?lang=en_us&edition=fundamental","pubTime":"2026-10-01 05:30","pubTimestamp":1790803800,"startTime":"0","endTime":"0","summary":"NEW YORK, Sept.  30, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a clinical stage biotechnology company focused on developing h","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/30/3372437/0/en/bright-minds-biosciences-to-participate-in-the-2026-fpwr-research-symposium-and-pws-family-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FPWR","BK4135","PWS","BK4139","DRUG","CNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658451129","title":"Press Release: Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658451129","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658451129?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:53","pubTimestamp":1786481580,"startTime":"0","endTime":"0","summary":"and the OLE  trial to assess the totality of. available efficacy and safety data and to support an informed. determination of next steps for the ARD-101 program. In June 2026, the. Company terminated the HERO and the OLE trial and does not currently. intend to resume these trials as previously designed.-- In May 2026, the Company announced that the U.S. Food and Drug. Administration  placed a full clinical hold on its investigational. new drug application  for ARD-101, related to the Company's. previously announced voluntary pause. The clinical hold applies to all. previously ongoing clinical studies under the IND, including the Phase 3. HERO trial evaluating ARD-101 for the treatment of hyperphagia in. patients with Prader-Willi Syndrome  and the Phase 3 OLE trial.Second Quarter 2026 Financial Highlights-- Cash Position: As of June 30, 2026, Aardvark had cash, cash equivalents. and short-term investments of $73.9 million, compared to $91.2 million as. of March 31, 2026. Based on curre","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","IND","AARD","HYLG","IDNA","MEDX","NVIB","GDOC","PWS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657184","title":"Press Release: Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657184","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657184?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046700,"startTime":"0","endTime":"0","summary":"-- Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP. manufacturing of clinical trial material underway. Initiation of the. Phase 3 RESCUE registrational program upon IND clearance.-- Sepranolone IND filing expected by year-end 2026 and initiation of Phase. 2 proof-of-concept study in Prader-Willi Syndrome upon IND clearance.-- Strengthened the leadership team with appointment of Bipin Dalmia as. -- Added to the Russell 2000 and Russell 3000 Indexes effective June. -- Cash balance of $217.7 million as of June 30, 2026, expected to fund. operations through 2029, including completion of the NDV-01 Phase 3","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","BK4139","BK4567","IE00BHPRN162.USD","LU2413666426.HKD","IE00BZ1G4Q59.USD","IE00BFXG1179.USD","IE00BN0W2V16.EUR","BK4585","LU0170899867.USD","LU0882574139.USD","LU2229751404.USD","LU2413666699.HKD","RLMD","LU0971096721.USD","LU2237443622.USD","IE00BN0W2T93.GBP","LU2237443895.HKD","LU1721428933.USD","LU2237443465.HKD","PSIL","ALLO","IE00B1BXHZ80.USD","IE00BN0W2W23.USD","R","BK4539","LU1721429741.USD","LU2746668461.USD","BK4588","LU2092937221.SGD","LU1543694498.USD","LU2089279066.USD","BK4007","BK4232","LU1721429402.USD","LU0149725797.USD","LU0347712357.USD","CMC","BK4006","LU2237443978.SGD","IND","LU2746668974.SGD","LENZ","EES","LU2237443549.SGD","BK4505","LU2041044095.USD","BK4121","A","PWS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656558874","title":"Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2656558874","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656558874?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:01","pubTimestamp":1785841260,"startTime":"0","endTime":"0","summary":"-- U.S. launch of IMCIVREE (setmelanotide) for acquired hypothalamic obesity (HO) starts strong with more than 400 patient start forms since FDA approval as of June 30, 2026 ---- Second quarter 2026 n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338168/0/en/Rhythm-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results-and-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2746668461.USD","BK4201","EC","LU2237443382.USD","LU0882574139.USD","LU0170899867.USD","LU2746668974.SGD","IE00BFXG1179.USD","LU0149725797.USD","LU2237443978.SGD","VUS","IE00BHPRN162.USD","LU2237443465.HKD","LU0971096721.USD","IE00B1BXHZ80.USD","LU2237443549.SGD","LU1363072403.SGD","IE00BZ1G4Q59.USD","BK4006","PWS","LU2237443622.USD","LU0267386448.USD","LU2237443895.HKD","CMC","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653226313","title":"Stock-bond Correlations Seen Rising","url":"https://stock-news.laohu8.com/highlight/detail?id=2653226313","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653226313?lang=en_us&edition=fundamental","pubTime":"2026-07-21 13:26","pubTimestamp":1784611560,"startTime":"0","endTime":"0","summary":"0526 GMT - The recent volatility in inflation leading economic indicators  is poised to push up stock-bond correlations, continuing a macro environment where bonds are less effective as equity diversifiers, Variant Perception says in a note. Variant's leading indicator for stock-bond correlations is ticking higher again, signaling positive expected correlations ahead, it says. \"This has been driven by rising volatility of our inflation LEI,\" it says. More frequent inflation shocks tend to restrict central bank policy flexibility, resulting in slower policy responses to negative shocks and driving up stock-bond correlations, it adds.  Dow Jones NewswiresJuly 21, 2026 01:26 ET Copyright  2026 Dow Jones & Company, Inc.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FIRS","CLSM","ARP","DIVZ","MAPP","PLGI","LGH","BAMO","CDC","CGUS","IUS","DDX","MDLV","DRSK","EAOR","BAMA","ILCV","ITDJ","MPAY","MRSK","FXD","HIDV","AOK","CLIX","BKDV","GAL","CGUI","PSC","EES","ELM","BSR","NDAA","DECU","EQRR","EAOA","FLV","QVOY","CGDV","IMCG","BNDW","ITDB","EAOM","MODL","PWS","PRVS","AOR","FT","LCG","DFUV","ADPV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643785500","title":"Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643785500","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643785500?lang=en_us&edition=fundamental","pubTime":"2026-06-16 04:01","pubTimestamp":1781553660,"startTime":"0","endTime":"0","summary":"-- Setmelanotide therapy achieved robust, sustained and clinically significant weight loss in patients with acquired HO at 2.5 years --  -- Bivamelagon therapy achieved progressive reductions in BMI a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/15/3312120/0/en/Rhythm-Pharmaceuticals-Announces-Multiple-New-Data-Presentations-from-MC4R-Agonists-in-Acquired-Hypothalamic-Obesity-HO-Bardet-Biedl-Syndrome-BBS-and-Prader-Willi-Syndrome-PWS-at-E.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4201","ENDO","PWS","VUS","BK4183","EC","AVP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643227716","title":"Rhythm Pharmaceuticals: Buy Rating Reiterated on Promising PWS Data and Large Market Opportunity; $105 Price Target Unchanged","url":"https://stock-news.laohu8.com/highlight/detail?id=2643227716","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643227716?lang=en_us&edition=fundamental","pubTime":"2026-06-15 18:35","pubTimestamp":1781519743,"startTime":"0","endTime":"0","summary":"In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Rhythm Pharmaceuticals, with a price target of $105.00. R...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/rhythm-pharmaceuticals-buy-rating-reiterated-on-promising-pws-data-and-large-market-opportunity-105-price-target-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/rhythm-pharmaceuticals-buy-rating-reiterated-on-promising-pws-data-and-large-market-opportunity-105-price-target-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PWS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643024272","title":"Rhythm Pharmaceuticals (RYTM) Stock After Positive Phase 2 PWS Data What Does The Valuation Suggest","url":"https://stock-news.laohu8.com/highlight/detail?id=2643024272","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643024272?lang=en_us&edition=fundamental","pubTime":"2026-06-15 02:13","pubTimestamp":1781460825,"startTime":"0","endTime":"0","summary":"Phase 2 PWS data and what it could mean for Rhythm Pharmaceuticals stock\nRhythm Pharmaceuticals (RYTM) recently reported six month interim Phase 2 data for setmelanotide in Prader Willi syndrome, highlighting clinically meaningful changes in BMI, fat mass, hyperphagia, and anxiety, and outlined plans to move into Phase 3 development.\nSee our latest analysis for Rhythm Pharmaceuticals.\nThe latest PWS data arrives after a mixed share price stretch, with the stock down 15.84% year to date on a...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-stock-after-positive-phase-2-pws","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-stock-after-positive-phase-2-pws","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","PWS","RYTM","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643185082","title":"Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2643185082","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643185082?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:01","pubTimestamp":1781294460,"startTime":"0","endTime":"0","summary":"BOSTON, June  12, 2026  (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with r","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/12/3311304/0/en/Rhythm-Pharmaceuticals-to-Announce-Interim-Six-Month-Phase-2-Results-Evaluating-Setmelanotide-in-Patients-with-Prader-Willi-Syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC","BK4201","PWS","AVP","VUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642286990","title":"Press Release: Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2642286990","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642286990?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:00","pubTimestamp":1781175600,"startTime":"0","endTime":"0","summary":"-- Dr. Quirk brings more than 20 years of neuroscience drug discovery and. development experience to lead Relmada's sepranolone program, building on. his tenure as Chief Scientific Officer at Sage Therapeutics.\"We are very pleased to welcome Mike to the Relmada team. His distinguished career in CNS drug discovery and development, including his leadership of research and scientific strategy at Sage Therapeutics, gives him a unique and highly relevant perspective on neuroactive steroid biology that we believe will be invaluable to the sepranolone program,\" said Sergio Traversa, Chief Executive Officer of Relmada Therapeutics.\"Sepranolone's mechanism of action -- selectively antagonizing the effects of allopregnanolone at GABA-A receptors without broadly disrupting GABAergic signaling -- represents a precise and elegant approach to modulating neural circuits that are dysregulated in compulsivity-related disorders like Prader-Willi syndrome,\" said Dr. Quirk, Senior Advisor -- Sepranolone P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","LU2229751404.USD","IE00BN0W2V16.EUR","BK4139","BK4539","BK4567","BK4505","BK4121","ALLO","LU1721428933.USD","PWS","BK4007","BK4585","LU2041044095.USD","LU2089279066.USD","RLMD","LU2413666426.HKD","LU1165135440.EUR","LU2092937221.SGD","LU0347712357.USD","LU1543694498.USD","LENZ","A","BK4588","CNS","IE00BN0W2W23.USD","LU2413666699.HKD","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639862225","title":"Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2639862225","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639862225?lang=en_us&edition=fundamental","pubTime":"2026-05-29 20:00","pubTimestamp":1780056000,"startTime":"0","endTime":"0","summary":"BOSTON, May  29, 2026  (GLOBE NEWSWIRE) --  Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/29/3303535/0/en/Rhythm-Pharmaceuticals-Announces-Seven-Abstracts-Accepted-for-Presentation-at-ENDO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENDO","AVP","EC","VUS","BK4201","BK4183","PWS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182460621","title":"FDA Imposes Full Clinical Hold on Aardvark's PWS Drug Candidate, Triggering Sharp Stock Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=1182460621","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182460621?lang=en_us&edition=fundamental","pubTime":"2026-05-16 03:10","pubTimestamp":1778872232,"startTime":"0","endTime":"0","summary":"Regulatory Blow to Core Pipeline The U.S. Food and Drug Administration has issued a full clinical hold order for Aardvark Therapeutics' core investigational drug ARD-101, freezing all ongoing...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","BK4588","PWS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635251837","title":"Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2635251837","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635251837?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:01","pubTimestamp":1778788860,"startTime":"0","endTime":"0","summary":"SAN DIEGO, May  14, 2026  (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3295315/0/en/Aardvark-Therapeutics-Plans-to-Unblind-HERO-and-OLE-Data-to-Inform-Path-Forward-Following-FDA-Clinical-Hold.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AARD","HERO","BK4588","LABU","BK4585","IND","PWS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633410771","title":"Press Release: Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633410771","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633410771?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:00","pubTimestamp":1778155200,"startTime":"0","endTime":"0","summary":"ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026. $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027. SAN DIEGO, May 07, 2026  -- Aardvark Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the first quarter ended March 31, 2026, and provided pipeline and business updates.\"We have been working closely with the FDA to comprehensively evaluate the data following the reversible cardiac observations in the healthy volunteer trial and are committed to determining the best path forward for our programs, patients and the broader PWS community,\" said Tien Lee, M.D., Founder and Chief Executive Officer of Aardvark. \"We remain focused on establishing a clear path forward for the Phase 3 HERO t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0054578231.USD","LU0211328371.USD","LU0708994859.HKD","LU1989763427.SGD","CCK","LU0029864427.USD","PWS","LU0310800379.SGD","LU1267930573.SGD","LU0211327993.USD","BK4007","AARD","LU0128526141.USD","LU1989763690.USD","LU0310799852.SGD","LU1267930490.SGD","HERO","LU0128525929.USD","BK4126","LU1803068623.USD","LU1892829315.USD","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633140419","title":"Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633140419","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633140419?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:00","pubTimestamp":1777978800,"startTime":"0","endTime":"0","summary":"-- IMCIVREE (setmelanotide) launched in the U.S. for acquired hypothalamic obesity; more than 150 patient start forms received in the first six weeks following FDA approval on March 19, 2026 -- -- Fir","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3287506/0/en/Rhythm-Pharmaceuticals-Reports-First-Quarter-2026-Financial-Results-and-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC","BK4201","VUS","BK4087","PWS","CHMP"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}]}}